Read our Annual Report 2018
MorphoSys is dedicated to become a fully integrated biopharmaceutical company. Our business strategy brings more value for patients, investors and partners.
First MorphoSys-antibody approved
Tremfya® (Guselkumab) now available in US, Europe and Canada!
We develop exceptional, innovative biopharmaceuticals
to improve the lives of patients suffering
from serious diseases.
Find out more about our therapeutic pipeline.
MorphoSys's vision
23/04/2019
MorphoSys and Galapagos Announce Initiation of GECKO Phase 2 Study with...
15/04/2019
MorphoSys Announces that its Licensee Janssen has Expanded Clinical...
01/04/2019
Dr. Sarah Fakih joins MorphoSys as Head of Corporate Communications and...
19/03/2019
MorphoSys and I-Mab Biopharma Announce Initiation of Pivotal Phase 2 Study...
07/03/2019
MorphoSys Provides Updates on L-MIND and B-MIND Clinical Trials of MOR208...
27/02/2019
MorphoSys Announces that its Licensee Janssen Has Received U.S. FDA...
19/02/2019
Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to...
19/02/2019
Ad hoc: Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His...
